Galapagos (NASDAQ:GLPG – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Galapagos to post earnings of ($0.06) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Galapagos Stock Performance
Shares of Galapagos stock opened at $28.95 on Monday. Galapagos has a 1-year low of $24.16 and a 1-year high of $42.46. The business has a 50-day moving average of $28.97 and a 200-day moving average of $27.78.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on GLPG shares. Raymond James lowered Galapagos from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd. Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a research note on Monday, September 9th. Finally, Leerink Partners initiated coverage on shares of Galapagos in a research note on Monday, September 9th. They set a “market perform” rating and a $24.00 price objective on the stock. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $31.00.
Galapagos Company Profile
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Read More
- Five stocks we like better than Galapagos
- Stock Market Sectors: What Are They and How Many Are There?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Election Stocks: How Elections Affect the Stock Market
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Pros And Cons Of Monthly Dividend Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.
